# OnCo record vebreltinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/vebreltinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "vebreltinib" ;
  schema:name "Vebreltinib"@en ;
  schema:alternateName "Bozitinib"@en, "APL-101"@en, "CBT-101"@en ;
  schema:description "Vebreltinib is a Chinese MET inhibitor approved in 2023 for lung cancers with a MET exon 14 skipping mutation, and the first drug tested in a phase 3 trial for glioblastomas carrying a PTPRZ1-MET fusion."@en ;
  schema:url <https://onco.cc/drugs/vebreltinib/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=PLB1001> ;
  onco:status "approved" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral selective MET tyrosine kinase inhibitor" ;
  onco:approval "CN 2023: Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:companies <https://onco.cc/companies/apollomics/>, <https://onco.cc/companies/avistone-biotechnology/> ;
  onco:trials <https://onco.cc/trials/nct06105619/>, <https://onco.cc/trials/nct05989542/>, <https://onco.cc/trials/nct06343064/>, <https://onco.cc/trials/nct03175224/>, <https://onco.cc/trials/nct06574347/> .